Biotechnology - Pharmaceutical, Cardio-vascular


Popular Filters

1 to 25 of 37 results

Lyxumia's delayed entrance into US anti-diabetes drug market could prove successful in the future, says GlobalData's analyst


French drug major Sanofi's (Euronext: SAN) decision to withdraw Lyxumia's (lixisenatide)...

BiotechnologyCardio-vascularDiabetesLyxumiaNorth AmericaPharmaceuticalRegulationResearchSanofi

Further highlights from European Society of Cardiology meeting


The ongoing European Society of Cardiology meeting in Amsterdam, Netherlands, continues to produce both…

ActelionalogliptinAmgenBiotechnologyCardio-vascularCytokineticsDiabetesomecamtiv mecarbilOpsumitPharmaceuticalResearchRespiratory and PulmonaryTakeda Pharmaceuticals

Amgen's US deal with Servier cleared


USA-based Amgen (Nasdaq: AMGN), the world's leading independent biotech firm, and privately-held French…

AmgenBiotechnologyCardio-vascularLicensingNorth AmericaPharmaceuticalProcoralanServier

Aegerion gains European approval for rare disease drug


The European Commission has approved US biopharma company Aegerion Pharmaceuticals' (Nasdaq: AEGR) Lojuxta…

Aegerion PharmaceuticalsBiotechnologyCardio-vascularEuropeJuxtapidKynamroLojuxtalomitapidePharmaceuticalRare diseasesRegulation

Amgen gains rights to Servier's heart drugs ivabradine and S38844


USA-based Amgen (Nasdaq: AMGN), the world's largest independent biotech firm, has entered a new collaboration…

AmgenBiotechnologyCardio-vascularEuropeivabradineLicensingNorth Americaomecamtiv mecarbilPharmaceuticalS38844Servier

Pharming and SIPI collaboration includes Ruconest marketing in China


Dutch biotech company Pharming Group (NYSE Euronext: PHARM) and Shanghai Institute of Pharmaceutical…

Asia-PacificBiotechnologyCardio-vascularLicensingPharmaceuticalPharmingResearchRuconestSinopharm Group

Negative late-stage trial results for Sanofi's iniparib and otamixaban


There was disappointing news from French drug major Sanofi (Euronext: SAN) this morning (June 3), as…


RedHill Biopharma views regulatory pathway for RHB-101 in CHF and hypertension


Emerging Israeli biopharma company RedHill Biopharma (TASE: RDHL) says that it recently concluded a positive…

BiotechnologyCardio-vascularCarvedilolLicensingPharmaceuticalRedHill BiopharmaRegulationResearchRHB-101

Amgen and Astellas link up on drugs for unmet medical needs in Japan


World leading independent biotech firm Amgen (Nasdaq: AMGN) has joined forces with Japanese drug major…

AmgenAnti-Arthritics/RheumaticsAsia-PacificAstellas PharmaBiotechnologyCardio-vascularOncologyPharmaceuticalResearch

Bristol-Myers gets added indication from US FDA for Sustiva; signs second deal with Ambrx


US pharma major Bristol-Myers Squibb (NYSE: BMY) says that the US Food and Drug Administration has approved…

AmbrxAnti-viralsBiotechnologyBristol-Myers SquibbCardio-vascularDiabetesLicensingNorth AmericaPharmaceuticalRegulationSustiva

FDA approves CSL's Kcentra and accepts Octapharma Octaplex BLA for reversal of anticoagulation


The US Food and Drug Administration has approved Kcentra (prothrombin complex concentrate, human) from…

BiotechnologyCardio-vascularCSL BehringCSL LimitedKcentraNorth AmericaOctapharmaOctaplexPharmaceuticalRegulation

AstraZeneca acquires AlphaCore; Merck Serono links with BioMed X


In line with its stated policy of targeted acquisitions, Anglo-Swedish drug major AstraZeneca (LSE: AZN)…

AlphaCore PharmaAstraZenecaBiotechnologyCardio-vascularMerck KGaAMerck SeronoMergers & AcquisitionsMetabolicsPharmaceuticalResearch

Gilead's Ranexa reduces angina frequency in patients with type 2 diabetes


US biotech firm Gilead Sciences (Nasdaq: GILD) has announced data from the Phase IV TERISA (Type 2 Diabetes…

BiotechnologyCardio-vascularDiabetesGilead SciencesPharmaceuticalRanexaResearch

News briefs: Pfizer's filiburvir; Sanofi's Plavix; EMA sued over transparency


Among a batch of news reported over the weekend, US drugs behemoth Pfizer (NYSE: PFE) has halted development…

AbbVieAnti-Arthritics/RheumaticsAnti-viralsBiotechnologyCardio-vascularEuropefiliburvirHumiraInterMuneNorth AmericaPfizerPharmaceuticalPlavixRegulationResearchSanofi

The Medicines Company gets rights to Alnylam's PCSK9 inhibitors program for cholesterol


USA-based The Medicines Company (Nasdaq: MDCO) has formed an exclusive global alliance with RNAi therapeutics…

Alnylam PharmaceuticalsAngiomaxBiotechnologyCardio-vascularLicensingPharmaceuticalThe Medicines Company

EMA consults on draft guideline for biosimilars containing low-molecular-weight heparins


The European Medicines Agency has launched a six-month public consultation on the revised guideline on…


FDA clears Sanofi and Isis' Kynamro for inherited cholesterol disorder


The US Food and Drug Administration yesterday approved Sanofi (Euronext: SAN) subsidiary Genzyme's orphan…

BiotechnologyCardio-vascularGenzymeIsis PharmaceuticalsKynamroNorth AmericaPharmaceuticalRare diseasesRegulationSanofi

Highlights from ASH meeting on Eliquis, Pradaxa, ALN-TMP and ibrutinib


During the 54th Annual Meeting of the American Society of Hematology (ASH) now taking place in Atlanta,…

ALN-TMPAlnylam PharmaceuticalsBiotechnologyBoehringer IngelheimBristol-Myers SquibbCardio-vascularEliquisibrutinibOncologyPfizerPharmaceuticalPharmacyclicsPradaxaResearch

News briefs: Auxilium/Pfizer accord; Novartis Signifor and RLX030 developments


US specialty drugmaker Auxilium Pharmaceuticals' (Nasdaq: AUXL) shares fell 7.2% to $18.60 at close of…

Auxilium PharmaceuticalsBiotechnologyCardio-vascularLicensingNovartisOncologyPfizerPharmaceuticalRare diseasesResearchRLX030SigniforXiaflexXiapex

Strong mid-stage results for Amgen's cholesterol drug candidate AMG 145


Global biotech leader Amgen (Nasdaq: AMGN) has announced positive results from the AMG 145 Phase II GAUSS…

AMG 145AmgenBiotechnologyCardio-vascularPfizerPharmaceuticalResearchRN316

Sanofi and Regeneron recruiting patients for cardiovascular outcomes trial with antibody to PCSK9 for hypercholesterolemia


French drug major Sanofi (Euronext: SAN) and US partner Regeneron Pharmaceuticals (Nasdaq: REGN) say…


1 to 25 of 37 results



Back to top